Eligibility for the Medicare GLP-1 Bridge will also be limited to Medicare beneficiaries who have not filled a prescription under their Part D plan for a GLP-1 in 2026, and who do not have a diagnosis with a condition that is a medically accepted indication for a GLP-1 drug that could be covered under Part D (specified by CMS as type 2 diabetes, obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)), even if they otherwise meet the clinical criteria
Epigallocatechin-3-Gallate Promotes the In Vitro Maturation and Embryo Development Following IVF of Porcine Oocytes
Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease
Whether your goal is brighter skin, a stronger immune system, or full-body detox, choosing a trusted provider ensures the safest path to success
For other Novo Nordisk medications, the threshold is 400% FPL (about $60,240 single)